OOIR: Observatory of International Research

Papers

(The H4-Index of JNCI-Journal of the National Cancer Institute is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Correction to: ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications	225
Vertical integration in oncology: what does it mean for patients with cancer?	162
Re: Deng and Heybati	151
Addressing Diversity, Equity, and Inclusion at the JNCI Journals	140
Factors associated with timely COVID-19 vaccination in a population-based cohort of patients with cancer	134
The National Cancer Institute Funding of Global Research: Lessons Learned and Opportunities Going Forward	124
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial	89
Response to Liu and Zhang	75
The Unrelenting Impact of Poverty on Cancer: Structural Inequities Call for Research and Solutions on Structural Determinants	72
Medication–Associated Phthalate Exposure and Childhood Cancer Incidence	69
Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC	69
Long-term aspirin use and cancer risk: a 20-year cohort study	69
Mediators of Racial Disparities in Heart Dose Among Whole Breast Radiotherapy Patients	69
Dyslipidemia and cardiovascular disease among childhood cancer survivors: a St. Jude Lifetime Cohort report	64
Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020	63
Ethylene oxide emissions and incident breast cancer and non-Hodgkin lymphoma in a US cohort	58
The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment	58
RE: Use of artificial intelligence for cancer clinical trial enrollment	56
Understanding risk factors for endometrial cancer in young women	54
Evaluating a blood test for colon cancer screening: how simulation modeling can inform clinical policy making and research	54
RE: Exploring the cross-cancer effect of circulating proteins and discovering potential intervention targets for 13 site-specific cancers	54
Method of primary breast cancer detection and the disease-free interval, adjusting for lead time	52
Pre- and post-diagnostic use of antihypertensive medications and stage I-III colorectal cancer survival: prospective cohort study	52
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination	51
Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study	49

Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study	48
Survivorship after adolescent and young adult cancer: models of care, disparities, and opportunities	48
Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study	46
Impact of knowledge of human papillomavirus positivity on cervical cytology performance in Latin America	46
Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas	46
Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer	46
Contribution of health insurance to racial and ethnic disparities in advanced-stage diagnosis of 10 cancers	45
Cancer control co-benefits of the climate-related provisions in the American Inflation Reduction Act	45
Common analgesics and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) Study	45
RE: Prevalence of cancer survivors in the United States	44
Evaluating colonoscopy quality by performing provider type	44
RE: Autoimmune disease and the risk of anal cancer in the US elderly population	43
Premature aging as an accumulation of deficits in young adult survivors of pediatric cancer	43
Correction to: Quality of Life in Older Adults After Major Cancer Surgery: The GOSAFE International Study	43
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line col	41
Impacts of an Opioid Safety Initiative on US Veterans Undergoing Cancer Treatment	40